The Value of Online Algorithms to Predict T-Cell Ligands Created by Genetic Variants.
Allogeneic stem cell transplantation can be a curative treatment for hematological malignancies. After HLA-matched allogeneic stem cell transplantation, beneficial anti-tumor immunity as well as detrimental side-effects can develop due to donor-derived T-cells recognizing polymorphic peptides that are presented by HLA on patient cells. Polymorphic peptides on patient cells that are recognized by specific T-cells are called minor histocompatibility antigens (MiHA), while the respective peptides in donor cells are allelic variants. MiHA can be identified by reverse strategies in which large sets of peptides are screened for T-cell recognition. In these strategies, selection of peptides by prediction algorithms may be relevant to increase the efficiency of MiHA discovery. We investigated the value of online prediction algorithms for MiHA discovery and determined the in silico characteristics of 68 autosomal HLA class I-restricted MiHA that have been identified as natural ligands by forward strategies in which T-cells from in vivo immune responses after allogeneic stem cell transplantation are used to identify the antigen. Our analysis showed that HLA class I binding was accurately predicted for 87% of MiHA of which a relatively large proportion of peptides had strong binding affinity (56%). Weak binding affinity was also predicted for a considerable number of antigens (31%) and the remaining 13% of MiHA were not predicted as HLA class I binding peptides. Besides prediction for HLA class I binding, none of the other online algorithms significantly contributed to MiHA characterization. Furthermore, we demonstrated that the majority of MiHA do not differ from their allelic variants in in silico characteristics, suggesting that allelic variants can potentially be processed and presented on the cell surface. In conclusion, our analyses revealed the in silico characteristics of 68 HLA class I-restricted MiHA and explored the value of online algorithms to predict T-cell ligands that are created by genetic variants.
Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
Dyantha I
DI
van der Lee
Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.|Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Margot J
MJ
Pont
Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
J H Frederik
JH
Falkenburg
Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
Marieke
M
Griffioen
D000465:Algorithms; D001665:Binding Sites; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D008024:Ligands; D013601:T-Lymphocytes / Q000166:cytology* / Q000276:immunology
D006680:HLA Antigens; D008024:Ligands